Aprea Therapeutics, Inc. (APRE) Operating cash flow 2017–2025
Aprea Therapeutics, Inc. (APRE) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$12.9MFY2025 · since FY2017: -$14.0M → -$12.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$12.9M | +4.9% |
| FY2024 | -$13.6M | -11.3% |
| FY2023 | -$12.2M | +51.3% |
| FY2022 | -$25.0M | +33.6% |
| FY2021 | -$37.7M | +9.8% |
| FY2020 | -$41.8M | -56.5% |
| FY2019 | -$26.7M | -75.1% |
| FY2018 | -$15.3M | -8.9% |
| FY2017 | -$14.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice